Public Citizen | Publications – Ten Myths of Drug Use

Ten Myths of Drug Use

Ten Myths Of Drug Use

In an article reprinted in the World Health Organization’s Essential Drugs Monitor in 1988, the FDA rebuts what it calls “10 charges or myths currently being raised, under the guise of independent dialogue, aimed at discouraging health professionals from prescribing or dispensing generic drugs”:
Myth 1: The 1984 action by Congress has eliminated safety and effectiveness testing requirements for generic drugs and has thus reduced the confidence that physicians and patients can have in the safety and effectiveness of generic drugs.
Fact 1: What the law in fact does is eliminate the unnecessary requirement for duplicative testing to redemonstrate the safety and effectiveness of active drug ingredients that have already been shown to be safe and effective by adequate and well-controlled studies and that have been widely used and accepted by the medical community for many years.
Myth 2: FDA requires pioneer drug manufacturers to study their drugs in thousands of patients, but it requires generic firms to test their drug products in 20 or 30 healthy volunteers.
Fact 2: This statement is misleading. Testing in a large number of patients is required for the pioneer drug in order to establish the safety and effectiveness of the new active drug ingredient. Once this has been established, the FDA need ensure only that others wanting to market a copy of the innovator’s product make their product correctly and that similar amounts of the drug enter the bloodstream.
Myth 3: Plasma level studies (measuring the amout of a drug in the blood) do not show how a drug acts at the site of action and therefore are not indicative of how well a drug will perform.
Fact 3: Once the active ingredient is shown to enter the bloodstream at the same rate and extent as the same active ingredient from another similar drug product, there is no currently recognized scientific basis to allege that the therapeutic effects or adverse effects of the two drugs will differ.
Myth 4: Bioequivalence studies (which measures the absorption of a drug into the blood (drug products made by different companies having the same absorption characteristics are called bioequivalent) are performed in healthy volunteers, who are usually in their twenties. However, many of the drugs are used primarily in elderly patients. These elderly patients can be expected to absorb and metabolize the drug differently than do the healthy volunteers. Therefore bioequivalence testing is not an indicator of how the drug will perform in patients.
Fact 4: The testing in healthy volunteers, which shows an equivalent blood level between the generic and the brand name product, is a strong indicator that the two tested dosage forms will behave the same under the same conditions. No one has demonstrated that two products found by conventional tests to be bioequivalent perform inequivalently in different patients. It is also preferable to subject healthy people, rather than already weakened or disabled patients, to the blood sampling and other discomforts of bioequivalence testing.
Myth 5: The FDA applies lower standards for generic approval compared to those required for the brand name products.
Fact 5: The lesser standard that is usually implied in such a statement relates to the safety and efficacy testing mentioned earlier. FDA in fact requires that the manufacturers in both instances follow good manufacturing practice, that they show that their drug is stable, that it is bioequivalent, and that it meets the same standards of identity, strength, quality and purity.
Myth 6: The FDA has no written rules or criteria for how it determines bioequivalence.
Fact 6: The FDA has required generic drugs to be bioequivalent to brand name products since the mid-1970s, and it published final regulations on bioequivalence in January 1977.
Myth 7: Because the FDA allows a variation of + 20 or 30% in the blood levels between the brand name and the generic products, generics may differ by as much as 60% from each other.
Fact 7: The test that the FDA employs and the standard that is applied is a statistical one. It is virtually impossible for a generic product to pass if it in fact differs in its average plasma level by 20% from the standard product. Deviations of more than 10% between generic and brand name products are rare; usually the differences are much less than 10%. 
 Myth 8: Brand-name drugs are made in modern facilities, while generics are often made in substandard facilities. Thus generics are of generally inferior quality.
Fact 8: No one has been able to demonstrate that the quality of generic drugs differs from that of the brand name counterparts. The rates of defects found by the FDA in both brand name and generic products are extremely low and speak well of the pharmaceutical industry’s care in producing prescription drugs. In fact, the innovator drug firms themselves account for an estimated 70-80% of the generic drug market. Thus, to believe generics are inferior, one would have to accept the premise that the research-oriented drug firms can’t adequately manufacture products other than the ones they pioneered. It is also true that many innovator drug firms distribute products made by smaller generic firms. It is unlikely they would continue such arrangements if they really doubted the ability of generic firms to manufacture quality products.
Myth 9: In calling drugs bioequivalent, the FDA overlooks documented cases of bioinequivalence.
Fact 9: While there have been a few well-known, documented cases of bioinequivalence, they are either examples from many years ago that have long since been corrected or problems resulting from drugs which had never gone through FDA’s approval system. The FDA is not aware of a single documented bioinequivalence involving any generic drug product that has been approved by FDA as bioequivalent.
Myth 10: Patients using generic products are more likely to suffer adverse reactions than those taking the brand name drug.
Fact 10: There is no evidence of a different rate of adverse drug reactions (ADRs) between brand name products and their generic equivalents. There have been some efforts recently by several brand name firms to stimulate reporting to FDA’s voluntary ADR system of adverse reactions to the products of their generic competitors. The FDA has vigorously opposed any such attempts.
The FDA has a public obligation to investigate thoroughly all allegations of drug product defects or failures. The agency has not found any of the allegations raised thus far in the brand name versus generic drug controversy to be valid. FDA also has an obligation to make known to health care professionals and to the public its conclusions that false or misleading reports are being generated.

You can purchase WORST PILLS BEST PILLS directly from Public Citizen by:

  • using our secure server to order with a major credit card
  • faxing your form to us
  • mail your order form along with check or money order for $16 (which includes shipping and handling) made payable to Public Citizen to Public Citizen, 1600 20th Street, N.W., Washington, DC 20009